Format

Send to

Choose Destination
Clin Infect Dis. 2008 Feb 15;46(4):567-70. doi: 10.1086/526775.

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.

Author information

1
Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA. kara.anthony@uphs.upenn.edu

Abstract

Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase- and extended-spectrum beta-lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available.

PMID:
18199038
DOI:
10.1086/526775
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center